



SUDA **Presentation to** **Shareholders**

14 October 2021

Board & Senior Management



Chairman

Paul Hopper

Over 25 years experience in the medical, healthcare & life sciences sectors. Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director or CEO, of more than fifteen companies in the US, Australia and Asia. Mr Hopper has founded, or technology seeded, six companies on the ASX and Nasdaq.



CEO and MD

Dr. Michael Baker

Over 15 years experience in scientific research, drug development and venture investing sectors. He was an Investment Manager with the leading Australian life science fund, BioScience Managers. He also conducted due diligence to shortlist investment opportunities and played an active role in managing portfolio companies.



Executive Director

David Phillips

Senior Business Development Executive with over 35 years in the healthcare industry. Including 23 years in GSK, 12 years in Biotech and as Managing Partner of SR One (GlaxoSmithKline's Corporate Venture Fund). During this period Mr Phillips was a member of the investment committee reviewing greater than 30 deals. David has been responsible for over 50 Pharma/Biotech deals and 10 M&A transactions.



Director

David Simmonds

David was a senior audit partner with Ernst & Young from 1989 to 2017. From 2008 to 2013, David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. David was a member of the Board of MS Research Australia.



Director

Dr. Debora Barton

Over 20 years of oncology experience, in academia, as a practicing physician and in the biotechnology/pharmaceutical industry. Served in key senior executive positions, including Carisma Therapeutics where Dr. Barton is currently the Chief Medical Officer, Iovance Biotherapeutics and Advanced Accelerator Applications, acquired by Novartis during Debora's tenure.






Agenda

- Managing Director's address
- Q&A (via online platform)
- Formal Business

Progress in 2021

- ZolpiMist® commercialization (Teva, STADA, other territories) – Australian partner secured
- Integrate and develop new technologies – iNKT cell therapy platform acquired
- Anagrelide formulation stabilisation
- Early-stage feasibility development work



ZolpiMist® - Insomnia

- ZolpiMist is SUDA's oral spray version of the insomnia drug Ambien/Stilnox, Sanofi's blockbuster¹
- Short-term insomnia has an estimated prevalence of 9.5% in the US²
- Sleep problems rose from 16% to **25%** during the COVID-19 pandemic (University of Southampton)³
- STADA to commercialise SUDA's TGA approved ZolpiMist in Australia (upfront payments and a double-digit royalty on the improved spray unit)
- Current Licensee populations:
 - Teva: ~350 million
 - STADA: ~25 million
 - Discussions with additional territories are underway
- SUDA to supply finished product

teva

STADA



ZolpiMIST™
(zolpidem tartrate) ORAL SPRAY

- Innovative Delivery
- Rapid Spray Absorption
- Fast Asleep



1. ZolpiMist has been approved by the TGA and the FDA and SUDA holds the rights to ZolpiMist outside of North America
2. <https://www.ajmc.com/view/insomnia-overview-epidemiology-pathophysiology-diagnosis-and-monitoring-and-nonpharmacologic-therapy>
3. <https://www.southampton.ac.uk/news/2020/08/sleeploss-lockdown.page>

SUDA
PHARMACEUTICALS LTD

iNKT Cell Therapy Platform – Highlights (acquired June 2021)

SUDA's **i**nvariant **N**atural **K**iller **T** (iNKT) cell therapy platform is at the forefront of immuno-oncology drug development

Pre-clinical studies show that:


- CAR-iNKT cells work **more efficiently** than conventional cell therapies
- CAR-iNKT cells outperform CAR-T cells, **rapidly clearing** the cancer cells and **increasing the number of surviving animals** by 1.5x when the CD1d protein is on the surface of cancer cells
- CAR-iNKT cells cause a **secondary remission** without additional treatment

In addition:

- CAR-iNKT cells provide dual-targeting to kill cancer cells
- The platform has “off-the-shelf” potential where one source can treat multiple patients
- Initial drug development will focus on haematological malignancies (blood cancers)

SUDA's iNKT Cell Therapy Platform

Healthy Donor



iNKT Cell Benefits

- iNKT cells are one of the most potent types of immune cells, acting rapidly
- iNKT cells bridge the adaptive and innate immune system
- iNKT cells activate components of the immune system to fight cancer cells
- The iTCR is common to all people so iNKT cells do not cause graft versus host disease
- Our preclinical data strongly supports use of iNKT cells with chimeric antigen receptors (CAR) to treat cancer



What are Chimeric Antigen Receptors (CARs)?

iNKT Cell




Immune cells are harvested from the healthy donor and the iNKT cell are specifically collected

CD19-CAR




The iNKT cells are genetically re-programmed with a CAR, supercharging them to seek out and destroy specific cancer cells

CAR19-iNKT Cell




Cancer Cell




Once administered to the cancer patient, the CAR-iNKT cells can seek out and destroy the cancer cells and recruit other components of the immune system


Different CARs to Target Different Cancers or Diseases




CAR 1 Blood Cancers



CAR 2 Solid Tumours



CAR 3 Other Diseases



CAR-iNKT Cell Therapy Development

24 months

- Recruit cell therapy manufacturing expert – Dr. Sandhya Buchanan ✓
- Enter into Research Agreement with Imperial College London ✓
- Recruit domain expertise board members – Dr. Debora Barton ✓
- Expand Scientific Advisory Board – Prof. Tassos Karadimitris (Chair); Dr. Reuben Benjamin; Dr. John Maher ✓
- Select GMP manufacturer
- GMP manufacturing of CAR19-iNKT cells for phase 1 clinical trial
- FDA pre-IND meeting
- FDA IND clearance
- Dose first patient in Phase 1 clinical trial for non-Hodgkin's lymphoma
- Develop additional products using other CARs

iNKT Cells Can Be Used Off The Shelf

Home › Topics › Precision Medicine › Allogene CAR-T Cancer Trials Placed on Clinical Hold by FDA

Topics Precision Medicine Oncology Gene Editing Gene Therapy Oncologics News & Features

Allogene CAR-T Cancer Trials Placed on Clinical Hold by FDA

October 12, 2021

*While this news is unfortunate for Allogene, and others working with T cells to create allogeneic cell therapy products, this may be an advantage for SUDA's iNKT cell therapy technology. iNKT cells **do not** need additional gene editing to be used off the shelf. They are naturally able to be used that way. Allogene is working with T cells and they need to use TALEN® (others use CRISPR), which enables them to delete additional genes to make their product off the shelf. In the case of Allogene, they delete two genes, TCRα and CD52. While we do not have the whole story yet, it is conceivable that additional genetic engineering may compromise the cells, which may have led to the "chromosomal abnormality."*

Shareholder Support to Transform the Company

SUDA
PHARMACEUTICALS LTD



arovella
T H E R A P E U T I C S

*“SUDA has undergone several transformations over its 22-year history. In order to fully realise our potential, we believe it is important to revitalise our image to enable our key stakeholders to see us from a fresh perspective. We have in-licenced what we believe is a transformational cancer therapy from Imperial College London. We will continue to build out from here, targeting diseases (“**arrow**”) with new (**novella**) platforms to help patients live longer and healthier lives.”*

Dr. Michael Baker
CEO and Managing Director

SUDA
PHARMACEUTICALS LTD

SUDA
PHARMACEUTICALS LTD

Q & A

Special Business Resolutions

Resolutions

1. Approval of change of Company name
2. Ratification and approval of previous allotment and issue of Shares
3. Approval of Employee Share Option Plan
4. Approval of allotment and issue of options to a related party: Dr. Michael Baker
5. Approval of issue of options to Baker Young Limited

CONTACT

Dr. Michael Baker
CEO & Managing Director
Email: mbaker@sudapharma.com
Mobile: +61 403 468 187

Disclaimer

1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Suda Pharmaceuticals Limited (**Company**). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.
2. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.
3. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.
4. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.
5. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.
6. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which it would be unlawful. In particular, the New Shares and Options have not been, and will not be, registered under the US Securities Act of 1933 (the "US Securities Act") and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed.
7. The New Shares and Options will be offered and sold in the United States only to (i) institutional accredited investors (as defined in Rule 501(a)(1), (2), (3) and (7) under the US Securities Act); and (ii) dealers or other professional fiduciaries organized or incorporated in the United States that are acting for a discretionary or similar account (other than an estate or trust) held for the benefit or account of persons that are not US persons and for which they exercise investment discretion, within the meaning of Rule 902(k)(2)(i) of Regulation S under the US Securities Act.